Please provide your email address to receive an email when new articles are posted on . Nasal glucagon was noninferior to intramuscular glucagon for treating hypoglycemia in Japanese adults with type ...

Please provide your email address to receive an email when new articles are posted on . Insulin-induced hypoglycemia was effectively treated with intranasal glucagon in adults with type 1 diabetes, ...

BERLIN — An investigational nasal glucagon offers the potential for an easier-to-use alternative to the injected version of the hypoglycemia rescue medication, new data suggest. Findings from a ...

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...

Glucagon is indicated for the treatment of severe hypoglycemia in patients with diabetes mellitus and as a diagnostic aid for use during certain radiologic examinations. Lupin is introducing glucagon ...

An investigational intranasal glucagon product may treat hypoglycemia just as effectively as intramuscular injections, a new study of adults with type 1 diabetes suggests. The intranasal glucagon ...

The Food and Drug Administration as approved the first generic of a drug used to treat severe hypoglycemia. The agency has approved a generic glucagon for injection, 1 mg, from Amphastar ...

Nasal glucagon is seen as a game-changing delivery method to replace the multistep system of mixing powder and liquid with a simple, 1-step spray. The FDA Wednesday approved Eli Lilly & Co.’s nasal ...

RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated ...

Today, the U.S. Food and Drug Administration approved the first generic of glucagon for injection USP, 1 mg/vial packaged in an emergency kit, for the treatment of severe hypoglycemia (very low blood ...